SCHEMBL7126472

SCHEMBL7126472

CC(C)(C)NS(=O)(=O)c1cccc(C2c3ccccc3C(=O)N2C(C(=O)O)c2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 1/20 0.43
TP53 P04637 15/20 0.42
MDM2 Q00987 15/20 0.42
MEN1 O00255 2/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
KCNA5 P22460 1/20 0.37
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKM P14618 1/20 0.35
CNR1 P21554 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125714 0.92 MDM2 (0.42) PARGTP53MDM2MEN1LMNA
SCHEMBL7125644 0.84 USP30 (0.39) PARGMEN1LMNAMAPTKMT2A
SCHEMBL7117720 0.82 MAPT (0.36) PARGMEN1LMNAMAPTKMT2A
SCHEMBL7117838 0.80 KDM4E (0.43) PARGMEN1LMNAMAPTKMT2A
SCHEMBL7122643 0.78 USP30 (0.36) PARGKCNA5
SCHEMBL7128790 0.74 CYP1A2 (0.42) PARGTP53MEN1LMNAMAPT
SCHEMBL7119405 0.73 F10 (0.48) PARG
SCHEMBL7130067 0.68 MGLL (0.33) PARGMEN1LMNAMAPTKMT2A
SCHEMBL7121882 0.67 RAB9A (0.38) PARGMEN1LMNAMAPTKMT2A
SCHEMBL7129114 0.66 MGLL (0.37) PARGMEN1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030114448-A1 Inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-06-19 US disclosed
WO-2002096873-A1 ISOINDOLE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF FACTOR XA MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114448-A1 Inhibitors of factor Xa SERPINC1, F11, TFPI PARG 1941/4885TP53 4647/4885MDM2 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.